Streetbeat News

Revenues

EXLS

ExlService Holdings (NASDAQ:EXLS) has significantly outperformed the market over the past 5 years, with an average annual return of 25.71%. A $1000 investment in EXLS 5 years ago would be worth $3,070.86 today. The article highlights the power of compounded returns.

Portfolio Pulse from Benzinga Insights

October 16, 2024 | 5:01 pm

WGS

GeneDx Holdings (NASDAQ:WGS) has received mixed analyst ratings, with a recent increase in average price targets. Analysts have raised their price targets, reflecting a more optimistic outlook. The company has shown strong revenue growth but faces challenges in profitability and asset utilization.

Portfolio Pulse from Benzinga Insights

October 16, 2024 | 5:01 pm

PGY

Pagaya Techs (NASDAQ:PGY) has been analyzed by 9 analysts, showing a range of opinions from bullish to bearish. The average 12-month price target is $25.22, a decrease from the previous $30.86. Analysts have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Pagaya Techs is a financial technology company with significant revenue growth but challenges in profitability and debt management.

Portfolio Pulse from Benzinga Insights

October 16, 2024 | 5:00 pm

OC

In the last three months, analysts have shown varied sentiments towards Owens-Corning (NYSE:OC), with recent ratings indicating a positive shift in price targets. The average 12-month price target has increased by 1.93% to $189.8. Analysts have adjusted their ratings and price targets, reflecting their response to market conditions and company performance. Despite revenue growth, Owens-Corning faces challenges with profitability, ROE, ROA, and debt management.

Portfolio Pulse from Benzinga Insights

October 16, 2024 | 5:00 pm

NVCR

NovoCure (NASDAQ:NVCR) has received mixed analyst ratings over the past three months, with a recent average price target of $28.0. Analysts have adjusted their ratings and price targets, reflecting their views on the company's market position and financial performance. NovoCure has shown strong revenue growth but faces challenges with profitability and asset returns.

Portfolio Pulse from Benzinga Insights

October 16, 2024 | 5:00 pm

BX

Blackstone's BREIT struggles to meet performance fee thresholds, impacting its earnings outlook. BREIT's modest gains in September were insufficient to trigger third-quarter performance fees, leading JPMorgan to lower its revenue projections for Blackstone's real estate segment. The fund faces significant challenges in achieving the necessary performance for future quarters.

Portfolio Pulse from Henry Khederian

October 16, 2024 | 4:51 pm

CTAS

Cintas (NASDAQ:CTAS) has significantly outperformed the market over the past 15 years, with an annualized return of 25.31%. A $1000 investment in Cintas 15 years ago would be worth $29,553.62 today. The article highlights the power of compounded returns over time.

Portfolio Pulse from Benzinga Insights

October 16, 2024 | 4:31 pm

MMC

Marsh & McLennan (NYSE:MMC) has outperformed the market over the past 15 years with an average annual return of 15.76%, surpassing the market by 3.99% annually. A $1000 investment in MMC 15 years ago would now be worth $9,254.28.

Portfolio Pulse from Benzinga Insights

October 16, 2024 | 4:31 pm

SCHW

Charles Schwab Corporation reported better-than-expected Q3 results, with a 5% revenue increase and a 9% rise in daily average trades. Analysts have mixed views, with JPMorgan and JMP Securities maintaining positive ratings and raising price targets, while Goldman Sachs remains cautious. Piper Sandler is cautiously optimistic about future trends.

Portfolio Pulse from Erica Kollmann

October 16, 2024 | 4:31 pm

ASPN

Aspen Aerogels shares rise following a conditional commitment for a DOE loan of up to $670.6 million. The company anticipates its second plant to generate $1.2 to $1.6 billion in revenue.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 4:21 pm